---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-089584"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:07:50.366440+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress

## Summary
- Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.
- BEACON CSU investigation rules out drug substance/product issues; focus shifts to clinical site activity.
- Investigation completion expected in Q4 2025 with KOL panel review for Phase 2b CSU study integration.
- Use of proceeds: continued development of briquilimab in mast-cell diseases and general corporate expenses.
- Common warrants exercisable at $2.92, 6-month lockout, 4-year term; pre-funded warrants at $0.0001 exercise.

## SEC filing metadata
- accession: 0001213900-25-089584
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/0001213900-25-089584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea0258026-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-089584
- JSON: https://secwatch.observer/filing/0001213900-25-089584.json
- Plain text: https://secwatch.observer/filing/0001213900-25-089584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.